News
SELB
--
0.00%
--
Selecta Biosciences to Participate at the Raymond James Human Health Innovation Conference
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR(TM) platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta's Chief Executive O...
GlobeNewswire · 5d ago
After recent weakness, gene therapy space offers a compelling opportunity: BTIG
dinn/iStock via Getty Images BTIG analysts Yun Zhong and Xu Zou witness “an attractive opportunity in gene therapy” after seeing that many players in the field are trading closer to
Seekingalpha · 5d ago
BTIG Initiates Coverage On Selecta Biosciences with Buy Rating, Announces Price Target of $10
BTIG analyst Yun Zhong initiates coverage on Selecta Biosciences (NASDAQ:SELB) with a Buy rating and announces Price Target of $10.
Benzinga · 6d ago
BTIG Starts Selecta Biosciences at Buy With $10 Price Target
MT Newswires · 6d ago
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers
Benzinga · 6d ago
Selecta Biosciences to Participate at the LifeSci Partners Genetic Medicines Summit 2021
WATERTOWN, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses,...
GlobeNewswire · 06/14 12:00
Shareholders Will Probably Hold Off On Increasing Selecta Biosciences, Inc.'s (NASDAQ:SELB) CEO Compensation For The Time Being
The underwhelming share price performance of Selecta Biosciences, Inc. ( NASDAQ:SELB ) in the past three years would...
Simply Wall St. · 06/12 09:46
BRIEF-Selecta Biosciences Announces Frontiers In Immunology Publication Showcasing Enhanced Hepatic Tolerogenic Potential Of Immtor
reuters.com · 06/01 13:04
Selecta Biosciences Announces Frontiers in Immunology Publication Showcasing the Enhanced Hepatic Tolerogenic Potential of ImmTOR(TM)
- Data demonstrate that ImmTOR enhances the tolerogenic environment in the liver-
GlobeNewswire · 06/01 12:00
Selecta Biosciences (SELB) Insiders Make Significant Share purchases Continuing the Trend of Last 90 Days
MT Newswires · 05/27 22:32
Selecta Biosciences Files For U.S. Patent Application Titled 'METHODS AND COMPOSITIONS FOR TREATING LIVER DISEASES AND DISORDERS'
https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=370&f=G&l=50&d=PG01&s1=%22*%22&p=8&OS=
Benzinga · 05/27 13:54
The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26)
Benzinga · 05/27 12:24
60 Biggest Movers From Yesterday
Gainers Lizhi Inc. (NASDAQ: LIZI) shares surged 57.6% to close at $6.84 on Wednesday.
Benzinga · 05/27 09:11
Insider buy at Selecta Biosciences (SELB) Extends the Trend of purchases over Last Quarter
MT Newswires · 05/26 22:32
CHMA, STIM, WMG and NXGN among after-hours movers
Gainers: [[CHMA]] +5.7%. [[STIM]] +5.2%. [[TMDX]] +3.3%. [[SELB]] +3.2%. [[CGEN]] +2.8%.Losers: [[WMG]] -12.8%. [[QMCO]] -4.8%. [[OKTA]] -4.2%. [[NXGN]] -3.9%. [[LIZI]] -3.8%.
Seekingalpha · 05/26 21:41
Why Selecta Biosciences' Stock Is Trading Higher Today
Selecta Biosciences (NASDAQ:SELB) shares are trading higher after a Form 4 filing showed insider purchasing from company Director Tim Springer.
Benzinga · 05/26 19:22
Insider Trends: Insider Purchase Continues Selecta Biosciences Positive Trend
MT Newswires · 05/26 17:34
41 Stocks Moving In Wednesday's Mid-Day Session
Gainers Asensus Surgical, Inc. (NYSE: ASXC) shares surged 34.4% to $2.7282. HC Wainwright & Co. initiated coverage on Asensus Surgical with a Buy rating and announced a price target of $4.
Benzinga · 05/26 16:25
Thinking about buying stock in AMC, Nabriva Therapeutics, GameStop, Pieris Pharmaceuticals, or Selecta Biosciences?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMC, NBRV, GME, PIRS, and SELB.
PR Newswire - PRF · 05/26 12:32
GME, AMC, RIOT and ZS among premarket gainers
Nabriva Therapeutics (NBRV) +51% as its Nabriva antibiotic meets primary endpoint.Pieris Pharmaceuticals (PIRS) +20%.Protagenic Therapeutics (PTIX) +11%.Zscaler (ZS) +11% on Q3 results.Urban Outfitters (URBN) +11% on Q1 results.Selecta Biosciences (SELB) +...
Seekingalpha · 05/26 12:21
Webull provides a variety of real-time SELB stock news. You can receive the latest news about Selecta through multiple platforms. This information may help you make smarter investment decisions.
About SELB
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its product candidates are in various stages of clinical and preclinical development. Its SVP technology encapsulates an immunomodulator in biodegradable nanoparticles to induce antigen-specific immune tolerance to mitigate the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. The Company's lead product candidate, SEL-212, is a combination of a therapeutic enzyme and its SVP technology designed to be the biologic treatment for gout.